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miR-223 Regulates Cell Growth and Targets
Proto-Oncogenes in Mycosis Fungoides/Cutaneous
T-Cell Lymphoma
Laura Y. McGirt1, Clare M. Adams2, Devin A. Baerenwald1, Jeffrey P. Zwerner1, John A. Zic1 and
Christine M. Eischen2
The pathogenesis of the cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), is unclear. MicroRNA
(miRNA) are small noncoding RNAs that target mRNA leading to reduced mRNA translation. Recently, specific
miRNA were shown to be altered in CTCL. We detected significantly reduced expression of miR-223 in early-stage
MF skin, and further decreased levels of miR-223 in advanced-stage disease. CTCL peripheral blood mononuclear
cells and cell lines also had reduced miR-223 as compared with controls. Elevated expression of miR-223 in these
cell lines reduced cell growth and clonogenic potential, whereas inhibition of miR-223 increased cell numbers.
Investigations into putative miR-223 targets with oncogenic function, including E2F1 and MEF2C, and the
predicted miR-223 target, TOX, revealed that all three were targeted by miR-223 in CTCL. E2F1, MEF2C, and TOX
proteins were decreased with miR-223 overexpression, whereas miR-223 inhibition led to increased protein levels
in CTCL. In addition, we showed that the 30-UTR of TOX mRNA was a genuine target of miR-223. Therefore,
reduced levels of miR-223 in MF/CTCL lead to increased expression of E2F1, MEF2C, and TOX, which likely
contributes to the development and/or progression of CTCL. Thus, miR-223 and its targets may be useful for the
development of new therapeutics for MF/CTCL.
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INTRODUCTION
MicroRNA (miRNA) are small, 18–22bp, noncoding RNAs that
negatively regulate protein translation (Lagos-Quintana et al.,
2001; Lau et al., 2001; Lee and Ambros, 2001; Bartel, 2004).
They elicit their effects on protein translation through the binding
of the 30 untranslated region (30-UTR) of mRNA, primarily causing
inhibition of translation or mRNA cleavage (Reinhart et al., 2000;
Llave et al., 2002; Bartel, 2004). Since the discovery that a
reduction in miR-15/16 may be a causal factor in the deve-
lopment of chronic lymphocytic leukemia (Calin et al., 2002),
there has been tremendous interest in the role of miRNA in the
development and progression of malignancies, as well as in the
use of miRNA in diagnostic signatures and cancer biomarkers.
Mycosis fungoides (MF) is the most common form of
cutaneous T-cell lymphoma (CTCL) and is increasing in
incidence (Weinstock and Horm, 1988). It classically
presents as patches and plaques, and progresses to tumors,
with eventual blood and visceral involvement. We have few
therapeutic options in advanced MF, and the 5-year survival
markedly reduces from 94% in stage IA to 48% in stage IIB
and to 18% in stage IV (Agar et al., 2010). In addition, little is
known about the pathogenesis of MF. Although efforts have
been made to identify potential causative infectious agents,
genetic mutations, and chronic antigenic stimulants, there is
no clear understanding of the etiology. Recently, studies
have identified altered miRNA expression in MF and CTCL.
Ballabio et al. (2010) reported decreased levels of miR-342
and miR-223 in Se´zary syndrome, a leukemic form of CTCL.
Another group identified a ‘‘diagnostic signature’’ of miRNA
(miR-155, -203, and -205) in CTCL to help differentiate it from
benign dermatoses (Ralfkiaer et al., 2011). It is clear that
miRNA are altered in MF/CTCL, but it is unknown what role
these alterations have in the oncogenesis or progression of the
disease. In a malignancy with increasing incidence, poor
5-year survival, and limited therapeutic options, it is impera-
tive that we make efforts to further understand MF/CTCL.
miR-223 is an intergenic miRNA under the control of its
own dedicated promoter (Pulikkan et al., 2010). Interestingly,
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it has been shown to be elevated in immature or blastic T-cell
malignancies (Mavrakis et al., 2011) but was found to have
reduced expression in CTCL, a mature T-cell malignancy
(Ballabio et al., 2010; Narducci et al., 2011; Ralfkiaer et al.,
2011). However, other groups have not detected a significant
alteration in miR-223 expression between CTCL and controls
(van Kester et al., 2011; Qin et al., 2012). On the basis of
these data, the precise alteration and role that miR-223 has in
CTCL has not been firmly established.
miR-223 has been shown to target potential oncogenic
transcription factors, E2F1 (Pulikkan et al., 2010) and the
myocyte-enhancing factor 2C (MEF2C) (Johnnidis et al., 2008),
in myeloid cells. A proposed miR-223 target, the thymocyte
selection–associated high mobility group box (TOX) that is
necessary for the development of CD4þ T-lymphocytes, was
recently found to be overexpressed in early-stage MF (Lewis
et al., 2005; Wang and El Naqa, 2008; Wang, 2008; Aliahmad
et al., 2012; Zhang et al., 2012). Here we show that miR-223
is expressed at decreased levels in MF and CTCL and that miR-
223 targets TOX, E2F1, and MEF2C in CTCL. Moreover,
increasing miR-223 led to reduced levels of TOX and the
oncogenic proteins, E2F1 and MEF2C, with an associated
decrease in CTCL growth and clonogenic potential, indicating
that miR-223 may be an inhibitor of CTCL development and/
or progression.
RESULTS
Decreased miR-223 levels in MF/CTCL
Evidence suggests that miR-223 levels are reduced in CTCL,
but its expression in MF has yet to be determined. To evaluate
miR-223 levels in MF, we analyzed 28 tissue samples of MF
(n¼ 8 early stage I–IIA, n¼ 20 advanced stage IIB–IV), 6 tissue
samples of benign inflammatory dermatoses (BID), and 7
tissue samples of normal skin controls. BID samples were
evaluated as they contain activated T cells and therefore serve
as a comparison control to malignant activated T cells in MF.
Quantitative real-time reverse-transcriptase–PCR (qRT-PCR)
revealed a significant decrease in miR-223 in MF as compared
with normal controls and BID (t-test, *Po0.001, **P¼ 0.004,
Figure 1a). There was no significant difference in miR-223
expression between the subgroups of BID (t-test, P¼ 0.16).
There was even greater reduction in miR-223 in advanced
MF as compared with early-stage MF (t-test, *Po0.001,
**P¼0.022, ***P¼ 0.036, Figure 1b). Peripheral blood mono-
nuclear cells (PBMC) from patients with leukemic MF and
Se´zary syndrome (n¼6) also demonstrated reduced miR-223
levels versus a pooled collection of PBMCs from Red Cross
donors (t-test, *Po0.001, Figure 1c). These data indicate that
miR-223 is expressed at a reduced level in both the diseased
skin and blood of MF patients as compared with normal
controls and that miR-223 diminishes as the clinical stage
advances.
To determine whether the decreased miR-223 levels
observed in patients with MF were similar in CTCL cell lines,
we measured miR-223 levels in two CTCL cell lines, HH and
Hut-78. We determined that the miR-223 levels in these two
CTCL cell lines were decreased as compared with levels in
CD4þ T cells from normal controls (n¼ 2, Figure 1d).
Specifically, Hut-78 had a greater than 45% reduction in
miR-223 expression as compared with control (t-test,
*Po0.001), and the miR-223 levels were almost undetectable
in HH cells (t-test, *Po0.001). Therefore, miR-223 is reduced
in CTCL lines as well as in patient samples, making the CTCL
lines a viable tool to test the effects of miR-223.
miR-223 inhibits CTCL cell growth and clonogenic potential
Although miRNA are altered within MF/CTCL, it is unknown
what role these changes have in the malignancy. To assess the
consequences of restoring miR-223 levels on CTCL growth,
we transfected miR-223 mimic into both HH and Hut-78
cells. The increase in miR-223 levels from the mimic was
determined by qRT-PCR (Figure 2a). By using the Trypan Blue
Dye exclusion assay, we measured a significant decrease
(30%) in viable cell numbers 72 hours post transfection
in the HH cells transfected with the miR-223 mimic as
compared with an RNA control (n¼ 5, t-test, *Po0.001,
Figure 2b). Similarly, with increased levels of miR-223 from
the mimic (Figure 2c), the Hut-78 cells showed a 29% and
20% decrease in viable cell numbers at 48 and 72 hours,
respectively, following miR-223 transfection (n¼ 3, t-test,
*Po0.001, Figure 2d). No difference in the number or
percentage of dead cells was detected when comparing
miR-223 mimic and RNA control samples at any of the times
evaluated.
To assess the effect of increased levels of miR-223 on CTCL
clonogenic capabilities, we transfected HH and Hut-78 cells
with either miR-223 mimic or RNA control and performed
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Figure 1. Reduced expression of microRNA (miR)-223 in mycosis fungoides
(MF). miR-223 expression levels relative to control small RNA RNU24 levels
by quantitative real-time reverse-transcriptase–PCR. (a) Skin biopsies from
subjects with MF (n¼ 8, early stage IA–IIA; n¼ 20, advanced stage IIB–IV),
normal controls (NC; n¼7) (*Po0.001), and benign inflammatory dermatoses
(BID; n¼ 6) (**P¼0.04). (b) Skin biopsies from NC and patients with early- or
late-stage MF (*Po0.001, **P¼0.022, ***P¼ 0.036). (c) Pooled control Red
Cross peripheral blood mononuclear cells (PBMCs) and cutaneous T-cell
lymphoma (CTCL) PBMCs (n¼ 6, *Po0.001). (d) CTCL cell lines (HH and
Hut-78) and CD4þ NC (n¼2, *Po0.001).
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methylcellulose assays. HH cells transfected with the miR-223
mimic had a 32.5% reduction in colony formation and Hut-78
cells had a 27.1% reduction in colony number as compared
with RNA control–transfected cells (n¼ 4, t-test, *Po0.001,
**P¼0.003, Figure 2e). We did not detect a difference in
colony size between the mimic and RNA control–transfected
cells.
To further assess the impact of altered miR-223 levels on
CTCL growth, an inhibitor of miR-223 was used to block its
function. Transfection of HH and Hut-78 cells with the miR-
223 inhibitor led to increased cell growth, as measured by
Trypan Blue Dye exclusion and MTS assays (Figure 3a and
data are not shown). The Trypan Blue Dye exclusion assay
showed a 24% increase in viable cell numbers in the HH cells
transfected with miR-223 inhibitor versus the cells transfected
with negative control (n¼ 3, t-test, *Po0.001, Figure 3a). The
Hut-78 cells also showed a statistically significant increase in
viable cell numbers (18%) in miR-223 inhibitor–transfected
cells by MTS assay (n¼ 3, t-test, **P¼0.013, Figure 3b).
Together, our results indicate that miR-223 inhibits CTCL cell
growth and clonogenic potential, but does not appear to have
an impact on apoptosis.
TOX is a direct target of miR-223
TOX, a protein normally expressed in thymocytes with unclear
function, was recently found to have an aberrant increased
expression in MF, suggesting a possible role in MF pathogen-
esis (Zhang et al., 2012). By using online miRNA target
databases (www.TargetScan.org and www.miRDB.org), we
identified TOX as a potential miR-223 target. The predicted
highly conserved miR-223-binding site (seed sequence) is
within the 30-UTR of TOX (Figure 4a). To test whether TOX
is a direct target of miR-223, we generated a luciferase
expression plasmid with the 30-UTR of TOX containing the
putative miR-223-binding site. We also generated a similar
plasmid with a mutated seed sequence, in which miR-223
could not bind. NIH-3T3 cells were co-transfected with the
wild-type or mutated TOX 30-UTR luciferase expression
plasmid and either miR-223 mimic or control RNA. The cells
with the miR-223 mimic and the TOX wild-type 30-UTR had a
significant reduction (53.6%) in luciferase activity, compared
with the RNA control–transfected cells (n¼3, t-test,
*Po0.001, Figure 4b). Moreover, the miR-223 mimic did
not induce a significant change in luciferase activity in cells
with the mutated 30-UTR of TOX (Figure 4b). These results
indicate that miR-223 binds to the 30-UTR of TOX and shows
that TOX is a direct target of miR-223.
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Figure 2. Increased microRNA (miR)-223 inhibits cutaneous T-cell lymphoma cell growth and decreases clonogenic potential. (a, c) miR-223 levels after
transfection with the miR-223 mimic in HH and Hut-78 cells. (b) Number of viable HH (n¼ 5) and (d) Hut-78 (n¼ 3) cells transfected with miR-223 mimic or
control RNA were determined at intervals by Trypan Blue Dye Exclusion assay (*Po0.001). (e) Methylcellulose clonogenic assays. Colony numbers in HH and
Hut-78 cells transfected with miR-223 mimic are relative to cells transfected with RNA control (n¼3; *Po0.001, **P¼ 0.003).
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Figure 3. Inhibition of microRNA (miR)-223 enhances cutaneous T-cell
lymphoma growth. (a) Number of viable HH cells transfected with miR-223
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miR-223 inhibitor or control (n¼ 3) were evaluated by MTS assay
(**P¼ 0.013).
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miR-223 targets E2F1, MEF2C, and TOX in CTCL
We have identified TOX as a direct miR-223 target, and miR-
223 has been previously shown to target the oncogenic
transcription factors E2F1 and MEF2C in myeloid cells
(Johnnidis et al., 2008; Pulikkan et al., 2010). To determine
whether these miR-223 targets are actually targeted by miR-
223 in CTCL and thus could contribute to the pathogenesis
of this disease, we first used qRT-PCR to assess the levels of
E2F1, MEF2C, and TOX mRNA in CTCL lines. We detected
significantly higher levels of E2F1, MEF2C, and TOX in HH
cells as compared with CD4þ controls (n¼3; t-test,
*Po0.001, **P¼0.007, ***P¼0.006, Figure 5a). In addition,
increased levels of E2F1 and TOX mRNA were observed in
Hut-78 cells (n¼3, t-test, *Po0.001, Figure 5a). Immunohis-
tochemistry also revealed increased TOX protein expression in
both early and advanced MF patient samples as compared
with normal and inflammatory controls (Figure 5b). There is
notable staining of TOX in lymphocytes within both Pautrier’s
microabscesses and MF tumors.
To more directly test the effects of miR-223 on its targets in
CTCL, we transfected HH cells with miR-223 mimic or control
RNA and evaluated mRNA and protein levels by qRT-PCR and
western blot, respectively, for E2F1, MEF2C, and TOX. miR-
223 mimic–transfected cells had a statistically significant
reduction in E2F1 (24.5%), MEF2C (31.1%), and TOX
(16.4%) mRNA versus RNA control–transfected cells (n¼4,
t-test, *P¼ 0.005, **P¼ 0.003, ***P¼0.019, Figure 6a). We
also assessed the protein levels of these targets. Western blots
showed decreased protein expression of E2F1, MEF2C, and
TOX in HH cells transfected with the miR-223 mimic com-
pared with the RNA control–transfected cells (Figure 6b).
Conversely, when the miR-223 inhibitor was transfected into
Hut-78 cells, we observed an increase in protein expression in
all three miR-223 targets (Figure 6c). These results suggest that
miR-223 targets E2F1, MEF2C, and TOX in CTCL cells, and
this likely contributes to MF pathogenesis.
DISCUSSION
miRNA have been shown to be altered within a wide variety
of malignancies, including CTCL and MF (Ballabio et al.,
2010; Ralfkiaer et al., 2011). It remains unclear whether these
miRNA are innocent bystanders, occurring secondarily from
other primary oncogenic mutations, or if they function as
initiators and/or drivers of the disease. Our current study
focused on miR-223 expression in early- and advanced-stage
MF and CTCL and on identifying how it may affect oncogenesis
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or disease progression. Most of the research on miR-223 has
centered on granulopoesis/myelopoesis, but less is known
about miR-223 within T-cell malignancies (Fazi et al., 2005,
2007; Fukao et al., 2007). We demonstrated that miR-223 was
significantly reduced in both early- an late-stage MF skin
samples as compared with normal and inflammatory skin
controls and that the levels decreased further as the clinical
stage advanced. In addition, there were lower levels of miR-
223 in CTCL PBMCs and cell lines compared with controls.
The fact that miR-223 was consistently reduced across a
variety of CTCLs and that it diminished as the disease
clinically progressed suggests that miR-223 has an important
role in the development and/or maintenance of MF/CTCL.
Indeed, CTCL cell growth was reduced by increasing miR-223
levels, while inhibiting miR-223 increased growth.
Clonogenic assays with miR-223 and CTCL cells revealed
similar findings. Our data indicate that miR-223 retards CTCL
growth by targeting pro-proliferative genes such as E2F1 and
MEF2C, resulting in decreased proliferation. However, we
cannot exclude the possibility that elevated miR-223 levels
may halt proliferation entirely in some CTCL cells, potentially
by inducing senescence. Therefore, our results indicate that
alteration of a single miRNA affects cell growth and clono-
genic potential in CTCL and provides evidence that miR-223 is
likely to have an integral part in disease development and/or
progression.
To address how miR-223 is capable of affecting CTCL cell
growth, we investigated potential and putative mRNA targets.
The oncogenic transcription factor E2F1 has been shown to
be a target of miR-223 in acute myeloid leukemia cells
(Pulikkan et al., 2010). E2F1 is a member of the E2F family
of transcription factors and is essential for cell cycle
progression (Johnson and Degregori, 2006). E2F1 functions
as an oncogene and is amplified and/or overexpressed in
many malignancies (Chen et al., 2009). We demonstrated that
E2F1 levels could be modulated by miR-223 in CTCL cells.
MEF2C was also shown to be targeted by miR-223 in myeloid
cells (Johnnidis et al., 2008). MEF2C is a transcription factor
elevated in a subset of the T-cell malignancy, T-cell acute
lymphoblastic leukemia. It has been shown to work
synergistically with the RAS and MYC oncogenes to induce
in vitro transformation of immortalized fibroblasts (Homminga
et al., 2011). We showed that miR-223 was able to regulate
MEF2C protein expression. Our data suggest that the reduced
levels of miR-223 in MF/CTCL allow for an increased
expression of the oncogenic transcription factors E2F1 and
MEF2C and may help to explain the dysregulated cell growth
in CTCL.
TOX is a small DNA binding protein that is tightly regulated
in the thymus during positive selection and is necessary
for CD4þ T-lymphocyte development. Once T cells have
matured, TOX is normally no longer expressed (Aliahmad
et al., 2012). However, TOX has recently been shown to be
overexpressed in mature CD4þ lymphocytes in MF (Zhang
et al., 2012), and we have also found that TOX is increased in
MF as compared with normal and inflammatory controls.
We have demonstrated that TOX is a direct target of miR-223,
and modulating miR-223 in CTCL cells led to significant
changes in TOX protein expression. Although the function
of TOX has yet to be established, it has been hypothesized
that TOX may influence E-protein transcription factors
and/or Id2, both of which are involved in lymphocyte
proliferation and differentiation (Aliahmad et al., 2012).
Loss of E proteins in T-cell development mimics TOX
overexpression in thymocytes (Jones and Zhuang, 2007).
Elevated levels of Id2 have been found in CTCL (Cotta et al.,
2008), and it has been suggested that Id2 hastens cell
cycle progression through interactions with the Rb family
(Lasorella et al., 1996). Therefore, miR-223 regulation of
TOX should have significant ramifications for MF/CTCL
growth.
Overall, MF/CTCL has been shown to have aberrant miRNA
expression, including reduced miR-223 levels. Our study
indicates that ‘‘correcting’’ this aberrancy leads to reduced
CTCL cell proliferation and reduced clonogenic potential,
which is mitigated through the effects of miR-223 target
mRNA/protein. Our data provide evidence that miR-223
contributes to the oncogenesis and/or progression of MF/CTCL
and that miR-223 or its targets should be evaluated for the
development of new therapeutics.
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MATERIALS AND METHODS
Tissue, blood, and cell lines
Frozen, banked PBMCs and 5–6 mm bisected skin biopsies from
MF/CTCL patients were identified retrospectively. The diagnosis
of MF/CTCL was confirmed through clinical and histological
evaluation and flow cytometric analysis. Skin biopsies from
patients with BID (e.g., psoriasis n¼ 3, spongiotic dermatitis
n¼ 3) were identified retrospectively through clinical and histo-
logical reports. Control normal skin was obtained through dis-
carded normal skin from surgery, and 6-mm biopsies were
performed and the samples bisected and frozen. Dr Utpal
Dave kindly provided control PBMC RNA from pooled Red
Cross donors. The HH (CRL-2105) and Hut-78 (TIB-161) CTCL
cell lines and NIH-3T3 cells were cultured as described by the
American Type Culture Collection (Manassas, VA). CD4þ cells from
normal donors were obtained from Sanguine Biosciences (Santa
Monica, CA). This study was approved by the Vanderbilt Institutional
Review Board.
RNA isolation and qRT-PCR
RNA was isolated from skin biopsies, PBMCs, and cell lines using
Trizol (Invitrogen, Grand Island, NY) according to the manufac-
turer’s protocol, with one exception. To enhance the isolation of
small RNA, the isopropanol precipitation step was performed
overnight at  20 1C. Sequences for b-actin, E2F1, MEF2C, and
TOX-specific qRT-PCR primer pairs were obtained from the Primer
Bank (Harvard Medical School) and synthesized by Eurofins MWG
Operon (Huntsville, AL). cDNA was generated and qRT-PCR was
performed with SybrGreen (SABiosciences, Valencia, CA) in
triplicate, as previously reported (Wang et al., 2008). The data
are expressed in 2DCt using b-actin as an internal reference.
TaqMan qRT-PCR for miRNA used TaqMan MicroRNA Assay
(Applied BioSystems, Grand Island, NY) in triplicate and was
compared with the expression of RNU24, an internal small RNA
control.
Transfection
HH cells (2 106 per sample) were prepared using the Nucleofector
Kit V (Lonza, Basel, Switzerland) and transfected with the X-005
program in the Nucleofector II instrument (Lonza). Hut-78 cells
(2 106 per sample) were prepared with the Nucleofector Kit R
(Lonza) and transfected with the V-001 program. The miRIDIAN
miR-223 mimic RNA oligomer and control RNA (100 nM) and the
miRIDIAN miR-223 hairpin inhibitor and inhibitor control (500 nM)
were used for transfection (Dharmacon, ThermoScientificBio,
Waltham, MA).
Cell viability and growth
Cell numbers and cell viability following the transfection of miR-223
mimic and inhibitor were determined by Trypan Blue Dye exclusion
assay and with the CellTiter 96 Aqueous One Solution Cell Prolifera-
tion Assay (MTS, Promega, Madison, WI).
Clonogenic assays
CTCL cells (5 103 ml 1) were plated in duplicate in methylcellulose
medium containing Iscove’s Modified Dulbecco’s Medium with
L-glutamine and 25mM HEPES (4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid; Gibco, Grand Island, NY), 20% fetal bovine serum, and
2.6% methylcellulose (per protocol MethoCult H4100, Stemcell Tech-
nologies, Vancouver, Canada). Twenty-four hours before plating, CTCL
cells were transfected with 100nM miR-223 mimic or RNA control as
described above. After 7 days (HH) or 10 days (Hut-78), colonies
consisting of 430 cells were quantified, and colony numbers were
compared between the cells transfected with miR-223 mimic and the
RNA control.
Luciferase vector generation and luciferase assay
A 60-mer of the 30-UTR of TOX containing the miR-223 seed
sequence and a 60-mer with a mutated (base substitutions) seed
sequence designed to prevent miR-223 from binding were cloned
into pMIR-REPORT (Invitrogen). NIH-3T3 cells were transfected with
100 ng of pMIR-REPORT wild-type TOX 30-UTR or mutant TOX 30-
UTR and 150 nM of miR-223 mimic or control RNA using Lipofecta-
mine 2000 (Invitrogen). The cells were also co-transfected with
100 ng of pMIR-REPORT vector expressing a b-galactosidase control
for normalizing transfection efficiency. Luciferase reporter gene
activity was assayed 24 hours after transfection using the luciferase
assay kit (Promega). b-Galactosidase activity was assayed by combin-
ing 50ml cellular lysate with 50ml b-galactosidase assay buffer (0.2 M
sodium phosphate buffer (pH 7.3), 2 mM MgCl2, 0.1 M b-mercap-
toethanol, ortho-nitrophenyl-b-D-galactopyranoside) for 1 hour, fol-
lowed by absorbance evaluation at 405 nm.
Immunohistochemistry
Slides were placed on the Leica Bond Max IHC stainer (Leica
Microsystems, Buffalo Grove, IL). Slides were deparaffinized, and
heat-induced antigen retrieval was performed using the Epitope
Retrieval 2 solution for 20 minutes. The slides were then incubated
with anti-TOX (Sigma-Aldrich, St Louis, MO; Catalog no.
HPA018322) at a 1:500 dilution for 1 hour.
Western blotting
Cell pellets were lysed with radio-immunoprecipitation assay buffer
(50 mM Tris, 150 mM sodium chloride, 1% Triton X-100, 0.1% sodium
dodecyl sulfate, 1% sodium deoxycholate) at 48 or 72 hours after
transfection (see above) with miR-223 mimic or RNA control or
miR-223 inhibitor or inhibitor control, respectively, and total
cellular proteins were western blotted, as previously described
(Alt et al., 2003). Antibodies specific for E2F1 (KH-95, Santa Cruz
Biotechnology, Santa Cruz, CA), MEF2C (4B10, Abcam, Cambridge,
MA), TOX (HPA018322, Sigma-Aldrich), b-actin (Sigma-Aldrich), and
a-tubulin (T6074, Sigma-Aldrich) were used.
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